Aurora Spine Stock Price, News & Analysis

Aurora Spine Corporation (OTCQB: ASAPF) announced FDA clearance for its ZIP™ series of minimally invasive spinal implants to treat Lumbar Spinal Stenosis, expanding its indications beyond degenerative disc disease and spondylolisthesis. This new indication aims to address a growing patient population, estimated to increase by 18 million over the next decade. The ZIP device features a patented one-step locking mechanism, reducing surgery time and recovery. CEO Trent Northcutt highlighted this achievement as a key milestone for Aurora, enhancing patient care options while supporting the company's growth strategy.

Aurora Spine Corporation (ASAPF) recently announced the issuance of United States Patent No: 11,331,199 for its ZIPFlex™ Technology. This patent covers a minimally invasive interlaminar implant designed for motion preservation and fusion in spinal surgeries. The ZIPFlex device allows surgeons to perform motion preservation operations or convert to fusion procedures as necessary. This innovation could enhance treatment options for patients suffering from lumbar spinal degenerative diseases. The company emphasizes its focus on simplifying complex surgical solutions for improved patient outcomes.

Aurora Spine Corporation (ASAPF) announced FDA 510(k) clearance for its innovative DEXA SOLO-L spinal fusion system, a first-of-its-kind 3D printed standalone ALIF device tailored to match patients' bone density. This development enhances Aurora's DEXA Technology Platform, marking a significant advancement in spinal surgery by personalizing implants. The CEO, Trent Northcutt, emphasized the potential for increased sales and surgeon adoption. This approval follows the company's commitment to innovation and expands their product range, previously including the DEXA-C cervical implant.

Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will release its financial results for Q1 2022 on May 23, 2022. This will be followed by a conference call scheduled for May 24, 2022, at 11:00 a.m. ET to discuss the results. The call can be accessed via phone at (844) 861-5497 or through a live webcast. A replay will be available until May 31, 2022. Aurora Spine specializes in designing innovative spinal implant technologies aimed at enhancing surgical outcomes.

Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) announced it will release its financial results for Q4 2021 on April 29, 2022. A conference call is scheduled for May 2, 2022, at 11:00 a.m. ET to discuss these results. The call can be accessed by phone or via webcast. Aurora Spine specializes in innovative medical devices aimed at enhancing spinal surgery outcomes and is focused on minimally invasive technologies.

Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will participate in the Lytham Partners Spring 2022 Investor Conference from April 4-7, 2022. The Company will host a panel discussion titled Simplifying the Complex – A Panel Discussion with Doctors that use Aurora Products on April 4 at 11:00 am ET, available on its website. Additionally, management will engage in virtual one-on-one meetings throughout the event. The webcast will be archived for later viewing. Aurora Spine specializes in innovative, minimally invasive spinal implant technologies.

Aurora Spine Corporation has achieved a significant milestone with the world's first surgical implantation of the DEXA-C patient matched implant at Cypress Pointe Surgical Hospital in Louisiana. This innovative device customizes spinal implants based on a patient's bone density, enhancing surgical outcomes and expanding access for older patients. Supported by peer-reviewed research, DEXA-C aims to reduce implant subsidence and improve fusion success rates. With the integration of Echolight technology, surgeons can now ensure the right implant density is selected for each patient, marking a transformative step in personalized spine surgery.

Aurora Spine Corporation (TSXV: ASG | OTCQB: ASAPF) announced a joint co-marketing agreement with Echolight Medical on February 24, 2022. This partnership focuses on integrating Aurora’s DEXA Technology-based spinal implants with Echolight’s radiation-free EchoS densitometer for assessing bone health. The collaboration aims to enhance patient care by providing quick and accurate bone quality analysis, which will aid in selecting appropriate spinal implants. Both companies anticipate improved healthcare access and increased support for orthopedic and spinal treatments.

Aurora Spine Corporation reports strong preliminary results for Q4 and FY2021, with a projected revenue increase of approximately 23% to about $3.0 million and over $10.5 million, respectively. Sales of ZIP® products surged by 145%, while SiLO™ SI Joint fusion devices contributed 10% to Q4 sales, up 84%. The company has introduced innovative products including the APOLLO™ cervical plate and DEXA-C™ cervical interbody system, expected to enhance market share. The U.S. SI Joint market alone is valued at $2.6 billion, presenting significant opportunities for growth.